Für einen optimalen Ausdruck erlauben Sie bitte den Druck von Hintergrundfarben und -bildern


Seite 1 von 12
Neuester Beitrag: 09.10.19 17:17
Eröffnet am: 06.01.14 21:53 von: Masterbroker. Anzahl Beiträge: 282
Neuester Beitrag: 09.10.19 17:17 von: sario Leser gesamt: 52.683
Forum: Börse   Leser heute: 25
Bewertet mit:

Seite: < 1 | 2 | 3 | 4 |
10 | 11 | 12 12  >  

3007 Postings, 2118 Tage MasterbrokerUSAAMARIN CORP. PLC REG.SHS(SP.ADRS NEW)/1 LS-,50 (WK

06.01.14 21:53
Nächste Rakette ???  
256 Postings ausgeblendet.
Seite: < 1 | 2 | 3 | 4 |
10 | 11 | 12 12  >  

2119 Postings, 3877 Tage MagnetfeldfredyAmarin

22.02.19 11:03
Neue Rekordverschreibungszahlen:

TRx: 37,934{vs 36,875;+2.87%}Sec+0.27% ATH NRx: 17,624{vs 16,563;+6.41%}Sec+2.34% ATH Ref: 20,310{vs 20,312;-0.01%}Sec-1.36% 2ndATH  

2119 Postings, 3877 Tage MagnetfeldfredyAmarin

22.02.19 16:21
Novartis (NVS) Rumored to Be in Talks to Acquire Amarin (AMRN) - Source
February 22, 2019 9:59 AM
Novartis (NYSE: NVS) is rumored to be in talks to acquire Amarin Corp. (NASDAQ: AMRN), according to a source claiming ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)  

558 Postings, 676 Tage TekoshinWas sagt ihr zu den Zahlen?

27.02.19 12:30

428 Postings, 1665 Tage RV10Wie zu erwarten...

27.02.19 12:38


558 Postings, 676 Tage TekoshinWird bald übernommen

27.02.19 16:18
Vllt schon diesen Monat  

4199 Postings, 853 Tage VassagoAMRN 21,18$ (+6%)

28.02.19 11:36

Amarin meldet Zahlen für 2018

  • Umsätze 229 Mio. $ (vgl. 181)
  • Verlust 116 Mio. $ (vgl. 68)

"2019 Revenue: Net total revenue for 2019 is anticipated to increase by more than 50% over 2018 to approximately $350 million, mostly from U.S. sales of Vascepa.  Amarin believes that continued quarterly variability in revenues is likely. This guidance assumes that the timing of the expanded label for Vascepa which Amarin is seeking, subject to FDA approval, will not be available until late 2019 or early 2020 such that the expanded label has little or no impact on revenue growth in 2019."



428 Postings, 1665 Tage RV10guten morgen...Wissen wir schon seit gestern

28.02.19 11:56


2119 Postings, 3877 Tage MagnetfeldfredyAmarin

28.03.19 10:37
Mega news, Vascepa von Amarin von der amerikanischen Diabetiker Organisation als standard of care aufgenommen, Millionen Diabetiker als Zielgruppe:


4199 Postings, 853 Tage VassagoAMRN 17,86$ (-4%)

01.05.19 20:19

Amarin meldet Zahlen für Q1/19

  • Umsätze 73 Mio. $
  • Verlust 24 Mio. $



2119 Postings, 3877 Tage MagnetfeldfredyLöschung

29.05.19 12:24

Moderator: jar
Zeitpunkt: 30.05.19 09:10
Aktion: Löschung des Beitrages
Kommentar: Urheberrechtsverletzung, ggf. Link-Einfügen nutzen



2119 Postings, 3877 Tage MagnetfeldfredyAmarin

30.05.19 15:17

2119 Postings, 3877 Tage MagnetfeldfredyAmarin

26.06.19 15:14

H.C. Wainwright Survey Shows Substantial Runway For Amarin Corporation's (AMRN) Vascepa
June 26, 2019 8:21 AM
H.C. Wainwright analyst Andrew Fein reiterated a Buy rating and $51.00 price target on Amarin Corporation (NASDAQ: AMRN) after conducted ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Analyst Comments

4199 Postings, 853 Tage VassagoAMRN 20,83$ (+8%, vorbörslich)

02.07.19 12:48

Vascepa Update & Anhebung der Umsatzprognose

  • Q2/19 Umsatzausblick 97-101 Mio. $
  • H1/19 Umsatzprognose 170-174 Mio. $
  • für 2019 wird die Umsatzprognose von 350 Mio. $ auf 380-420 Mio. $ angehoben



2119 Postings, 3877 Tage MagnetfeldfredyAmarin

10.07.19 15:32
Why Amarin Stock Is Up 63% So Far in 2019
[Motley Fool]
Beth McKenna, The Motley Fool
,Motley Fool•July 10, 2019
What happened

Shares of Irish biotech Amarin (NASDAQ: AMRN) are up 14.2% so far this month, through Tuesday, July 9.

This rise follows the stock's 42.5% gain in the first half of 2019, according to data from S&P Global Market Intelligence. The S&P 500 returned 18.4% over this period.

Amarin's year-to-date gain is a hearty 62.7% through July 9, versus the broader market's 20.2% return.
A pile of six see-through, light-gold capsules on a flat surface.
A pile of six see-through, light-gold capsules on a flat surface.

Image source: Getty Images.
So what


On July 2, Amarin shares surged 16.3% following the company increasing its full-year 2019 revenue guidance to a midpoint of $400 million, up from $350 million. The raise was driven by strong demand for Vascepa, its omega-3 fatty-acid drug derived from fish oil that's currently approved to treat patients with high triglyceride levels.

This demand could be only a start, however, as Amarin and its investors are eagerly anticipating the U.S. Food and Drug Administration's decision on a huge label expansion. In late September, investors should learn whether the FDA has given the green light to Vascepa for the treatment of patients at risk for major adverse cardiovascular events, including heart attacks or strokes.

As background: Amarin stock skyrocketed last September after the company released robust results of its Reduce-It cardiovascular outcomes study. As I previously wrote, "The study showed that Vascepa ... reduced the risk of major adverse cardiovascular events by 25% in patients already taking statin drugs compared to those receiving a placebo, which is a highly statistically significant result."

AMRN Chart
AMRN Chart

Data by YCharts.

First Half of 2019

Amarin stock likely got a tailwind in the first half of the year from the strong overall market. That said, we can attribute its outperformance of the market to several catalysts, including:

   Jan. 9: Shares popped 8.1% following the company's optimistic presentation at the J.P. Morgan Healthcare Conference.
   Jan. 10: Shares soared 22.1% on market chatter about pharmaceutical giant Pfizer being interested in making a bid for Amarin.
   Feb. 22-27: Shares gained 21.5% in the four market days leading up to and including the company's release of its fourth-quarter and full-year 2018 results, driven by investor optimism about Vascepa sales on the heels of the Reduce-It study. Indeed, investors were right to be hopeful, as Vascepa's Q4 revenue rose 44% year over year to $77.3 million.
   May 29: Shares surged 11.6% after Amarin announced that the FDA had granted an expedited review of Vascepa for patients at risk of major adverse cardiovascular events. This moved the timetable for the agency's decision to six months after the application submission rather than the more usual 10 months.

Now what

Take heart, investors: The FDA's decision on Vascepa's label expansion should be less than three months away, in late September. Look for Amarin stock to react accordingly.  

4199 Postings, 853 Tage VassagoAMRN 18,50$

19.07.19 16:28

400 Mio. $ ADS Offering

  • 22,22 Mio. ADS´s zu je 18$



2119 Postings, 3877 Tage MagnetfeldfredyAmarin

24.07.19 16:03
Amarin up 3% premarket on draft ICER report confirming Vascepa value
Jul. 24, 2019 9:07 AM ET|About: Amarin Corporation plc (AMRN)|By: Douglas W. House, SA News Editor

Amarin (NASDAQ:AMRN) perks up 3% premarket on light volume on the heels of a draft report from the non-profit Institute for Clinical and Economic Review (ICER) concluding that Vascepa (icosapent ethyl) and Johnson & Johnson's (NYSE:JNJ) blood thinner Xarelto (rivaroxaban) provide clinical benefit, reduce cardiovascular risk and "fall below commonly cited thresholds for cost-effectiveness." In other words, the products are priced appropriately for the value delivered.

JNJ is off a fraction premarket.

See all stocks on the move »  

2119 Postings, 3877 Tage MagnetfeldfredyAmarin

24.07.19 18:10
Amarin Is Just Running Up That Hill; Peak Sales Could Reach $10B, Says Analyst
,TipRanks•July 24, 2019

Biotech Amarin (AMRN) is one of Wall Street’s biggest standouts, with shares skyrocketing 566% in just the last year. Its fish-oil derivative drug Vascepa is already clinically proven to lower very high triglycerides without raising bad cholesterol. What’s more, recent trials revealed it could also cut cardiovascular risks by 25% in patients with abnormally high triglyceride levels. The FDA will either approve or reject this potentially very lucrative label expansion on September 28, and approval should send shares soaring.

An approval would make Vascepa the first therapy, as an adjunct to diet, proven to reduce cardiovascular events when used to treat patients with persistent elevated triglyceride levels and other cardiovascular risk factors. It is this large, unmet medical need for potentially tens of millions of patients which Vascepa has been targeting for many years.

Ahead of this key date, Cantor Fitzgerald analyst Louise Chen has just released a very bullish report on Amarin. She made the call following the company's recent equity raise. “The proceeds should help accelerate the growth of Vascepa, and we think the peak sales potential of this drug could be $5B-$10B” writes Chen. FactSet forecasts $2.1B of sales by 2024.

Indeed Amarin currently shows a ‘Strong Buy’ Street consensus with all six analysts covering the stock bullish. Meanwhile the average analyst price target of $33 suggests shares can surge over 80% from current levels.

On July 18, AMRN announced the pricing of the underwritten public offering of 22.2 million shares at a price of $18 per shares. The gross proceeds of this offering are expected to be ~$400 million, before deducting expenses. Note that Amarin has also granted the underwriters a 30-day option to purchase up to an aggregate of 3.3 million additional shares.

As the company’s press release reveals, AMRN intends to use the net proceeds from the offering for multiple purposes. These include: (1) doubling its existing sales force for Vascepa to 800, increasing advertising, and supporting expanded commercial operations; (2) increasing the commercial supply of Vascepa from third-party drug product suppliers; and (3) for general corporate purposes.

“Amarin also may use a portion of the net proceeds to acquire strategic assets, although it currently has no agreements or commitments in this regard” the statement says.

Looking ahead the next catalysts to keep an eye on are as follows: 1) as you would expect, the potential FDA approval AMRN's supplemental new drug application (sNDA) seeking an expanded indication for Vascepa in the US based on the positive results of AMRN's REDUCE-IT study, 2) pick up in sales from expanded label as well as increased sales and promotional efforts, and 3) Amarin becoming profitable by 2020 (according to the analyst’s estimate).

Net-net, Chen reiterates her buy rating with a $35 price target (93% upside potential). “We continue to think that AMRN is an interesting asset in a consolidating space” she says.  

4199 Postings, 853 Tage VassagoAMRN 19,24$ (+4%, vorbörslich)

31.07.19 14:15
  • 101 Mio. $ Umsatz in Q2/19



1946 Postings, 3538 Tage Tamakoschyzu Q2

01.08.19 11:19





428 Postings, 1665 Tage RV10Das war's...Bis Sylvester wieder bei 3€

09.08.19 08:08


4199 Postings, 853 Tage VassagoAMRN 15,25$ (-14%)

09.08.19 16:28

FDA will nun doch einen Panel durchführen (14.11.19)



752 Postings, 3614 Tage millemaxBin heute zu 15 USD eingestiegen

09.08.19 19:35
...ich habe schon lange auf diesen Einstieg hier noch gewartet...
1.Tranche zu 15 Dollar...bei weiterem Nachgeben der Kurse würde ich weiter nachkaufen.
Den Panel Termin erachte ich als absolut unproblematisch außer einer gewissen Verzögerung jetzt um einige Wochen oder Monate.


2 Postings, 369 Tage joeblow2Biologic Basis of EPA to Reduce Atherosclerosis

17.08.19 17:34
Biologic Basis of EPA to Reduce Atherosclerosis Burden:


2119 Postings, 3877 Tage MagnetfeldfredyAmarin

19.08.19 18:48
AHA, American Heart Associaton, empfiehlt Vascepa für Triglyceridsenkung und Reduktion und von Herzinfarkt, Schlaganfällen und herzbedingten Todesfällen, super Meldung für die Patienten und Amarin mit Vascepa:

Published on: August 19, 2019
Prescription Omega-3 Fatty Acids Effectively Reduce Triglycerides, AHA Says in Advisory
Mary Caffrey
Interest in omega-3 fatty acids have increased since publication of the results of REDUCE-IT.
Today’s prescription omega-3 fatty acid drugs effectively lower triglycerides, the American Heart Association (AHA) said today in an advisory report,1 which warned that patients should avoid treating themselves with fish oil supplements not approved by the FDA.

Prescription forms of omega-3 fatty acids can reduce triglyceride levels 20% to 30% for those who are diagnosed with high levels. Data from CDC show that about 25% of Americans have triglycerides above 150 mg/dL, which is above what is recommended;2 those with levels from 200 to 400 mg/dL are considered to have high triglycerides, and a those with 500 mg/dL have very high triglycerides.

Triglycerides are fats that circulate in the bloodstream. Once triglycerides reach 200 mg/dL, patients are at risk of atherosclerosis (narrowing of the arteries), heart attacks, and strokes. Those with triglycerides above 500 mg/dL are also at risk of pancreatitis, an inflammation of the pancreas.

“From our review of the evidence from 17 randomized, controlled clinical trials on high triglyceride levels, we concluded that treatment with 4 grams daily of any of the available prescription choices is effective and can be used safely in conjunction with statin medicines that lower cholesterol,” said Ann Skulas-Ray, PhD, an author of the advisory published in AHA journal Circulation,1 said in a statement.

The advisory comes as evidence accumulates that a formulation of omega-3 fatty acid, icosapent ethyl, sold as Vascepa, offers benefits beyond lowering triglycerides. The medication, a highly purified eicosapentaenoic acid (EPA), sold in a 4-gram capsule, has been shown to reduce the risk of heart attacks, strokes, and cardiovascular events by 25% among patients with high triglycerides when taken with a statin.3

FDA first approved Vascepa in 2012 to treat patient with high triglycerides. Amarin, which makes Vascepa, is seeking a cardiovascular indication for the medication from FDA. A decision had been expected in late September; however, FDA has now scheduled an advisory committee meeting for November 14, 2019, and a decision is not expected before December.

Highlights from today’s advisory include:

   Two forms of omega-3 fatty acids are sold and no studies comparing them have been published, so the advisory does not recommend one over the other. Besides EPA, the other formulation combines EPA with docosahexaenoic acid (DHA).

   The advisory said that “contrary to perception,” the EPA + DHA combination does not elevate low-density lipoprotein (LDL) cholesterol for most people with high triglycerides, although those with very high triglycerides (above 500 mg/dL) may see higher LDL cholesterol while taking this formulation.
   Physicians should rule out other causes of high triglycerides, such as hypothyroidism and poorly managed type 2 diabetes, before prescribing medication, and urge patients to adopt a healthy lifestyle as well.
   The review panel that issued the advisory found that prescription omega-3 drugs can reduce triglyceride levels with or without statin therapy.  
   In a statement, the AHA warns, “People should not try to treat the condition themselves with non-prescription fish oil supplements, since they are not reviewed or approved,” by FDA.

“Dietary supplements containing omega-3 fatty acids are not regulated by the FDA. They should not be used in place of prescription medication for the long-term management of high triglycerides,” said Skulas-Ray, who is an assistant professor in the Department of Nutritional Sciences at the University of Arizona in Tucson.

In an earlier advisory released in 2017, AHA said there was not enough evidence to support using omega-3 fatty acid supplements to prevent heart disease in the general population.

Interest in omega-3 fatty acids has increased with publication of results from REDUCE-IT, the study that identified Vascepa’s ability to reduce major cardiovascular events. REDUCE-IT was presented at the 2018 annual meeting of AHA, and additional results were presented at the 2019 meeting of the American College of Cardiology. The advisory notes that results from a trial involving a EPA + DHA medication are due in 2020.


   Skulas-Ray AC, Wilson PWF, Harris WS et al on behalf of the American Heart Association. Omega-3 fatty acids for the management of hypertriglyceridemia. Circulation. 2019;140.
   Carroll MD, Kit BK, Lacher DA. Trends in elevated triglyceride in adults: United States, 2001–2012. NCHS data brief, no 198. Hyattsville, MD: National Center for Health Statistics. 2015. https://www.cdc.gov/nchs/products/databriefs/db198.htm.
   Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380(1):11-22. doi: 10.1056/NEJMoa1812792.


179 Postings, 2751 Tage sariowie ist eure Meinung?

09.10.19 17:17
Wohin mit Amarin?  


Seite: < 1 | 2 | 3 | 4 |
10 | 11 | 12 12  >  
   Antwort einfügen - nach oben